Abstract
The central nervous system plays an important role in regulating bone metabolism in health and in disease with a number of neurotransmitters been reported to influence bone cell activity through a central relay. In keeping with this, recent studies demonstrated that endocannabinoids and their receptors are involved in the pathogenesis of osteoporosis. The endocannabinoids anandamide and 2-arachidonylglycerol are found in the skeleton and numerous studies also showed that bone cells express the cannabinoid receptors CB1 and CB2 and the orphan receptor GPR55. Pharmacological and genetic inactivation of CB1, CB2 and GPR55 in adult mice suppress bone resorption, increase bone mass and protect against bone loss, suggesting that inverse agonists/antagonists of these receptors may serve as anti-resorptive agents. In the ageing skeleton however CB1 and CB2 receptors have a protective effect against age-dependent bone loss in both male and female mice. CB1 receptor deficiency in aged mice results in accelerated age-dependent osteoporosis due to marked increase in bone resorption and significant reduction in bone formation coupled to enhanced adipocyte accumulation in the bone marrow compartment. Similar acceleration of bone loss was also reported in CB2 deficient mice of similar age but found to be associated with enhanced bone turnover. This review summarises in vitro and in vivo findings relating to the influence of cannabinoid ligands on bone metabolism and argues in favour of the exploitation of cannabinoid receptors as targets for both anabolic and anti-resorptive therapy for treatment of complex multifaceted bone diseases such as osteoporosis.
Keywords: Cannabinoid, osteoporosis, bone, anti-resorptive, anabolic, Rimonabant©, CB1, CB2, GPR55
Current Neuropharmacology
Title: Cannabinoid Receptors as Target for Treatment of Osteoporosis: A Tale of Two Therapies
Volume: 8 Issue: 3
Author(s): Aymen I. Idris
Affiliation:
Keywords: Cannabinoid, osteoporosis, bone, anti-resorptive, anabolic, Rimonabant©, CB1, CB2, GPR55
Abstract: The central nervous system plays an important role in regulating bone metabolism in health and in disease with a number of neurotransmitters been reported to influence bone cell activity through a central relay. In keeping with this, recent studies demonstrated that endocannabinoids and their receptors are involved in the pathogenesis of osteoporosis. The endocannabinoids anandamide and 2-arachidonylglycerol are found in the skeleton and numerous studies also showed that bone cells express the cannabinoid receptors CB1 and CB2 and the orphan receptor GPR55. Pharmacological and genetic inactivation of CB1, CB2 and GPR55 in adult mice suppress bone resorption, increase bone mass and protect against bone loss, suggesting that inverse agonists/antagonists of these receptors may serve as anti-resorptive agents. In the ageing skeleton however CB1 and CB2 receptors have a protective effect against age-dependent bone loss in both male and female mice. CB1 receptor deficiency in aged mice results in accelerated age-dependent osteoporosis due to marked increase in bone resorption and significant reduction in bone formation coupled to enhanced adipocyte accumulation in the bone marrow compartment. Similar acceleration of bone loss was also reported in CB2 deficient mice of similar age but found to be associated with enhanced bone turnover. This review summarises in vitro and in vivo findings relating to the influence of cannabinoid ligands on bone metabolism and argues in favour of the exploitation of cannabinoid receptors as targets for both anabolic and anti-resorptive therapy for treatment of complex multifaceted bone diseases such as osteoporosis.
Export Options
About this article
Cite this article as:
I. Idris Aymen, Cannabinoid Receptors as Target for Treatment of Osteoporosis: A Tale of Two Therapies, Current Neuropharmacology 2010; 8 (3) . https://dx.doi.org/10.2174/157015910792246173
DOI https://dx.doi.org/10.2174/157015910792246173 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
Call for Papers in Thematic Issues
Advances in Neuroinflammation and Neuroprotection: Mechanisms and Therapeutic Frontiers
It offers a comprehensive exploration of neuroinflammatory and neuroprotective pathways that play central roles in a range of neurological disorders, including stroke, traumatic brain injury, and neurodegenerative diseases such as Alzheimer’s and Parkinson’s. This issue invites research on the cellular and molecular mechanisms driving neuroinflammation, such as the roles of ...read more
Advances in paediatric and adult brain cancers: emerging targets and treatments
Brain tumors are the most common solid tumors affecting children and adolescents, with up to 5,000 children diagnosed per year. Pediatric brain tumors, because of their location, are often untreatable and their clinical management can cause significant long-term impairment to intellectual and neurological function with epilepsy and neurodegeneration. Other than ...read more
Emotion (Dys)regulation: An integration of Pharmacological, Neurobiological, and Psychological Frameworks
Emotion regulation is a critical aspect of mental well-being and interpersonal relationships. To fully understand and effectively address emotion regulation, an integrative approach that considers pharmacological, neurobiological, and psychological frameworks is essential. Pharmacological interventions, such as medications targeting neurotransmitter imbalances, can play a significant role in managing emotional dysregulation. Understanding ...read more
Enhancing Neuropharmacology with Home Cage Monitoring, Advanced Delivery and Stimulation Technologies, and Artificial Intelligence
Home cage monitoring (HCM) technologies have revolutionized neuropharmacological research by enabling continuous, non-invasive observation of rodents in their natural environments. Complementary advancements such as 24/7 continuous drug delivery systems (e.g., implantable pumps) and wireless neurostimulation methods—including optogenetics—offer precise methods for modulating neural activity and administering pharmacological agents without disrupting the ...read more

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cytotoxic and Apoptogenic Activity of a Methanolic Extract from the Marine Invertebrate Ciona intestinalis on Malignant Cell Lines
Medicinal Chemistry Therapeutic Options for the Management of Aromatase Inhibitor- Associated Bone Loss
Endocrine, Metabolic & Immune Disorders - Drug Targets Patent Annotations
Recent Patents on Anti-Cancer Drug Discovery Diabetic Gastroenteropathy: Soothe the Symptoms or Unravel a Cure?
Current Diabetes Reviews Dithiocarbamate-based coordination compounds as potent proteasome inhibitors in human cancer cells
Mini-Reviews in Medicinal Chemistry “Metabolic Aspects” In Inflammatory Bowel Diseases
Current Drug Delivery Testicular Germ Cell Tumors: A Paradigm for the Successful Treatment of Solid Tumor Stem Cells
Current Cancer Therapy Reviews The Immunohistochemical Expression of the E-Cadherin, Alpha-Catenin,Beta-Catenin and Gamma Catenin Proteins in Epithelial Ovarian Tumours: Relationship with Clinicopathologic Parameters and Patient Survival
Current Women`s Health Reviews Review of Recent Clinical Developments and Patents for the Treatment of Autoimmune and Inflammatory Diseases by Mesenchymal Stromal Cells
Recent Patents on Regenerative Medicine Biomimetic Drug Delivery Systems Oriented by Biological Function in Tumor Targeting
Current Drug Targets Antioxidant Effects of Chalcones during the Inflammatory Response: An Overall Review
Current Medicinal Chemistry Netrin and DCC: Axon Guidance Regulators at the Intersection of Nervous System Development and Cancer
Current Drug Targets Synthesis, in vitro Antiproliferative and Antiinflammatory Activities, and Kinase Inhibitory effects of New 1,3,4-triarylpyrazole Derivatives
Anti-Cancer Agents in Medicinal Chemistry Activation of the dsRNA-Activated Protein Kinase PKR in Mitochondrial Dysfunction and Inflammatory Stress in Metabolic Syndrome
Current Pharmaceutical Design CypD: The Key to the Death Door
CNS & Neurological Disorders - Drug Targets Medicinal Plants as a Source of New Therapeutic Products: Genus Mentha and the Potential Antimicrobial Activity of Extracts and Essential Oils
Current Traditional Medicine The Role of Diabetes Mellitus in Diseases of the Gallbladder and Biliary Tract
Current Diabetes Reviews TGF-β2 Signaling in High-Grade Gliomas
Current Pharmaceutical Biotechnology Gynaecological Cancer Diagnostics: 99mTc-Cisplatin Complex as a Future Approach for Early, Prompt and Efficient Diagnosis of Gynaecological Cancer
Current Medical Imaging Local Melatonin Regulates Inflammation Resolution: A Common Factor in Neurodegenerative, Psychiatric and Systemic Inflammatory Disorders
CNS & Neurological Disorders - Drug Targets